Genentech, Inc.

Other

Forma Tm, LLC

Hoffmann-la Roche Inc.

Hydro-aire, Inc.

Valo Health, Inc.

F. Hoffmann-la Roche Ag

Mark Edward Zak

Lei Zhang

Po-Wai Yuen

Wei Li

Peter Scott Dragovich

Guiling Zhao

Paul Gibbons

Timm R Baumeister

Christine Edwards

Yun-Xing Cheng

Xiaozhang Zheng

Kenneth W Bair

F Anthony Romero

Terry Kellar

Snahel Patel

Simon Charles Goodacre

Rohan V Mendonca

Yamin Zhang

Xiongcai Liu

Nicholas Charles Ray

Emily J Hanan

Joseph P Lyssikatos

Stephen Colin Price

Robert Andrew Heald

Po-wai Yuen

Francis Gosselin

Wendy Lee

Naomi S Rajapaksa

Marian C Bryan

Jessica Grandner

Daniel G M Shore

Joanne Frances Mary Hewitt

Bing-Yan Zhu

Bingsong Han

Janusz Jozef Kulagowski

Zhongguo Wang

Alexandre Joseph Buckmelter

Jian Lin

Steven R Magnuson

Hazel Joan Dyke

Dominic J Reynolds

Christopher Hurley

Michael Siu

Nancy-Ellen Haynes

Sharada Shenvi Labadie

James John Crawford

Richard Pastor

Chase C Smith

Johannes Cornelius Hermann

Srinivasan Babu

Kyungjin Kim

Stuart Ward

Thomas E Rawson

Aihe Zhou

Gregory Hamilton

Karl H Clodfelter

Janet L Gunzner-Toste

Nathan Robert Scott

Matthew W Cartwright

Wendy Liu

Lin Yi

Bohdan Waszkowycz

Anthony F Romero

Rongbao Hua

Mohammed Sajad

Limin Cheng

Rebecca Pulk

Michael Koehler

Tony Johnson

Stefan Gradl

Phillippe Bergeron

Po-Wei Yuen

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases

Compounds of Formula (I): salts thereof and methods of making and use as Janus kinase inhibitors are described herein.

Therapeutic compounds, compositions and methods of use thereof

Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.

Pyrazolochlorophenyl compounds, compositions and methods of use thereof

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Amido spirocyclic amide and sulfonamide derivatives

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Pyrazolopyrimidine inhibitors of JAK kinases and uses thereof

Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

Pyrazolopyrimidine compounds and methods of use thereof

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Amido-benzyl sulfone and sulfoxide derivates

Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Therapeutic compounds and compositions, and methods of use thereof

Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

Triazolopyridine compounds, compositions and methods of use thereof

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives

Growing community of inventors

San Mateo, CA, United States of America

Mark Edward Zak